| Opportunity ID: |
320418 |
| Opportunity Number: |
RFA-CK-20-004 |
| Opportunity Title: |
Prevention Epicenters Program: Protecting patients from infections, antibiotic resistance and other adverse events |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.084 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Public or Private Institutions of Higher Education, including: Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions U.S. Territory or Possession Eligible Agencies of the Federal Government Nonprofits Other Than Institutions of Higher Education Faith-based or Community-based Organizations Regional Organizations Bona Fide Agents: a Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with "Other Attachment Forms" when submitting via www.grants.gov. Federally Funded Research and Development Centers (FFRDCs): FFRDCs are operated, managed, and/or administered by a university or consortium of universities, other not-for-profit or nonprofit organization, or an industrial firm, as an autonomous organization or as an identifiable separate operating unit of a parent organization. A FFRDC meets some special long-term research or development need which cannot be met as effectively by an agency's existing in-house or contractor resources. FFRDC's enable agencies to use private sector resources to accomplish tasks that are integral to the mission and operation of the sponsoring agency. For more information on FFRDCs, go to http:// ecfr.gpoaccess.gov /cgi/t/text/ text-idx?c=ecfr& sid=512ff78311f427c00454772dcf21523a&rgn=div8&view=text&node=48:1.0.1.6.34.0.1.18& idno=48 Small, minority, and women-owned businesses Research institutions Hospitals Community-based organizations |
| Agency Code: |
HHS-CDC-HHSCDCERA |
| Agency Name: |
Department of Health and Human Services
Centers for Disease Control and Prevention – ERA |
| Posted Date: |
Sep 09, 2019 |
| Last Updated Date: |
Sep 09, 2019 |
| Estimated Synopsis Post Date: |
Dec 12, 2019 |
| Fiscal Year: |
2020 |
| Award Ceiling: |
$750,000 |
| Award Floor: |
$500,000 |
| Estimated Total Program Funding: |
$40,000,000 |
| Expected Number of Awards: |
11 |
| Description: |
The purpose of this notice of funding opportunity (NOFO) is to: Form a collaborative research infrastructure between experts in relevant fields to respond to joint priorities to protect patients. Conduct research that will support the translation of basic, epidemiologic and technologic discoveries into new strategies for preventing and decreasing the incidence of healthcare-associated infections (HAIs), antimicrobial resistance (AR) and other adverse events in all types of healthcare facilities in the United States. |
| Version: |
1 |
|
